Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.59 |
| ▸ | RXRB | P28702 | 7/20 | 0.59 |
| ▸ | RXRG | P48443 | 7/20 | 0.59 |
| ▸ | RARA | P10276 | 3/20 | 0.52 |
| ▸ | RARB | P10826 | 3/20 | 0.52 |
| ▸ | RARG | P13631 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908129 | 0.95 | RXRA (0.59) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6906120 | 0.88 | RXRA (0.77) | RXRARXRBRXRGRARARARB | |
| SCHEMBL3982018 | 0.84 | RXRA (0.72) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6905696 | 0.83 | RXRA (0.77) | RXRARXRBRXRGRARARARB | |
| SCHEMBL9318900 | 0.82 | RXRA (0.56) | RXRARXRBRXRGRARARARB | |
| SCHEMBL24055013 | 0.80 | RXRA (0.65) | RXRARXRBRXRGRARARARB | |
| SCHEMBL8436552 | 0.79 | RARB (0.55) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6901737 | 0.75 | RXRA (0.61) | RXRARXRBRXRGRARARARB | |
| SCHEMBL13716998 | 0.75 | RXRA (0.50) | RXRARXRBRXRGRARARARB | |
| SCHEMBL13479198 | 0.75 | RARB (0.58) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
| EP-0963199-A1 | TREATMENT OF DISEASE STATES WHICH RESULT FROM NEOPLASTIC CELL PROLIFERATION USING PPAR-GAMMA ACTIVATORS AND COMPOSITIONS USEFUL THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998029113-A1 | TREATMENT OF DISEASE STATES WHICH RESULT FROM NEOPLASTIC CELL PROLIFERATION USING PPAR-GAMMA ACTIVATORS AND COMPOSITIONS USEFUL THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885RXRB 5/4885RXRG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.